Accessible version Argenx SE Positive phase 3 myositis data opens the door for Vyvgart in rheumatology Reiterate Rating: BUY | PO: 1,136.00 USD | Price: 992.39 USD Positive phase 3 data clear the path for Vyvgart in INM Argenx (ARGX) reported positive topline phase 3 data from the ALKIVIA trial evaluating efgartigimod in myositis. The trial met the primary endpoint in the overall population and showed statistical significance in the INM subgroup but not in DM. ARGX is committed to securing a label for INM a ...